Attached files
file | filename |
---|---|
EX-32.1 - EXHIBIT 32.1 - REGENERX BIOPHARMACEUTICALS INC | tv488786_ex32-1.htm |
EX-31.1 - EXHIBIT 31.1 - REGENERX BIOPHARMACEUTICALS INC | tv488786_ex31-1.htm |
EX-10.48 - EXHIBIT 10.48 - REGENERX BIOPHARMACEUTICALS INC | tv488786_ex10-48.htm |
EX-10.47 - EXHIBIT 10.47 - REGENERX BIOPHARMACEUTICALS INC | tv488786_ex10-47.htm |
10-K - 10-K - REGENERX BIOPHARMACEUTICALS INC | tv488786_10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration Nos. 333-168252, 333-152250 and 333-111386) of RegeneRx Biopharmaceuticals, Inc. (the “Company”) of our report dated March 29, 2018, on our audits of the financial statements of RegeneRx Biopharmaceuticals, Inc., which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, as of December 31, 2017 and 2016 and for the years then ended, included in this Annual Report on Form 10-K for the year ended December 31, 2017.
/s/ CohnReznick LLP |
Tysons, Virginia
March 29, 2018